Salivary Physiology and Protective Functions

Saliva is a complex fluid secreted at rates of 0.5-1.5 mL per minute at rest (unstimulated) and 3.5-7.0 mL per minute during stimulation (mastication, gustatory, or thermal stimuli). Approximately 1.0-1.5 liters of saliva are produced daily from three major gland pairs (parotid, submandibular, sublingual) and hundreds of minor salivary glands distributed throughout oral cavity.

Salivary composition includes water (99%), electrolytes (sodium, potassium, calcium, phosphate, fluoride), proteins (mucins, amylase, lysozyme, lactoferrin, immunoglobulins), and microorganisms. This complex composition enables saliva to perform critical protective functions that profoundly influence oral health.

Antimicrobial Protection

Salivary antimicrobial proteins actively suppress bacterial and fungal growth:

Lysozyme (concentration: 20-30 mg/100mL saliva) is a muramidase enzyme hydrolyzing bacterial cell wall peptidoglycan, causing bacterial lysis. Particularly effective against Gram-positive bacteria and oral streptococci. Lactoferrin (concentration: 0.1-5 mg/100mL) binds iron essential for bacterial growth, inhibiting Streptococcus mutans colonization and acid production by 40-50%. Iron-binding capacity creates iron deficiency in biofilm, limiting bacterial virulence. Immunoglobulin A (IgA) (concentration: 25-50 mg/100mL) blocks bacterial adhesin receptors on epithelial cells, preventing initial bacterial colonization. Secretory IgA-antibody complexes agglutinate bacteria, facilitating mechanical clearance. Salivary peroxidase (SPO) (concentration: highly variable, 1-100 units/mL) generates thiocyanate ions that oxidize bacterial proteins, reducing metabolic activity by 30-60%.

Patients with saliva flow rates <0.1 mL/min (severe xerostomia) lose 70-90% of antimicrobial protection, predisposing to oral candidiasis (Candida albicans colonization increases 50-100 fold), bacterial infection, and aggressive caries.

Buffering and Remineralization

Saliva maintains pH 6.2-7.4 through bicarbonate buffering systems. Critical pH for enamel demineralization is 5.5; saliva's buffering capacity prevents pH drops below 5.5 for extended periods, limiting demineralization.

Bicarbonate buffering capacity is measured in mL of 0.1 N hydrochloric acid required to lower pH from 7.0 to 3.0. Normal buffering capacity ranges from 5-100 mL/min; xerostomia patients show 50-90% reduction in buffering capacity, allowing acidic pH to persist 3-5 times longer than normal.

Phosphate and fluoride ions in saliva enable remineralization of demineralized enamel subsurface lesions. Calcium and phosphate concentrations (8-10 mg/100mL calcium, 20-30 mg/100mL phosphate) promote conversion of demineralized calcium phosphate into apatite, reversing incipient caries lesions if buffering capacity permits pH recovery.

Mechanical Clearance and Lubrication

Saliva's flow rate mechanically clears food debris, bacterial plaque, and metabolic byproducts from oral surfaces. Reduced flow (xerostomia) results in debris accumulation, plaque retention, and increased caries/periodontal risk by 300-400%.

Mucins (glycoproteins: 5-15 mg/100mL saliva) provide lubrication and protective coating of oral mucosa. Mucin deficiency causes oral mucosal atrophy, erosion, and discomfort. Patients with severely reduced mucin production report significant eating difficulty.

Assessment of Salivary Function

Quantitative Testing: Salivary Flow Rate

Unstimulated salivary flow rate (USFR) measured over 5 minutes with patient sitting quietly, no oral stimulation:
  • Normal: 0.3-0.5 mL/min
  • Low: 0.1-0.3 mL/min (increased caries/candidiasis risk)
  • Severely reduced: <0.1 mL/min (severe xerostomia symptoms, high disease risk)
Stimulated salivary flow rate (SSFR) measured over 5 minutes during mastication (gum chewing or paraffin wax chewing):
  • Normal: 1.0-2.0 mL/min
  • Reduced: 0.5-1.0 mL/min
  • Severely reduced: <0.5 mL/min
Measurement protocol: Patient sits quietly; saliva is collected in preweighed container without external stimulation (USFR) or with mastication stimulus (SSFR) for exactly 5 minutes. Weight change is converted to mL (1 gram ≈ 1 mL).

Qualitative Testing: Buffering Capacity and Antimicrobial Markers

Buffering capacity measured via titration: Saliva (1 mL) is mixed with 0.1 N hydrochloric acid until pH reaches 3.0; volume of acid required indicates buffering reserve. Normal buffering requires 5-100 mL; xerostomia patients show proportionally reduced values. Quantitative PCR analysis can measure specific antimicrobial protein levels (lysozyme, lactoferrin, IgA) but is research-focused, not routine clinical practice.

Practical assessment: Rapid salivary tests (Saliva-Check, Salivary Diagnostic Systems) provide semi-quantitative buffering assessment chairside using color-change indicators.

Xerostomia: Etiology and Prevalence

Xerostomia (subjective dry mouth sensation) and hyposalivation (objectively reduced salivary flow) affect 15-20% of the general population, increasing to 40-70% in adults >65 years.

Medication-Induced Xerostomia

Approximately 20% of commonly prescribed medications cause salivary gland hypofunction through anticholinergic mechanisms or direct gland toxicity. Common culprits include:

  • Anticholinergics: Antihistamines (diphenhydramine, loratadine), tricyclic antidepressants (amitriptyline, nortriptyline), atropine-like agents
  • Antihypertensives: Diuretics (furosemide), beta-blockers, ACE inhibitors
  • SSRIs/SNRIs: Sertraline, fluoxetine, paroxetine, venlafaxine
  • Antiparkinsonian agents: Benztropine, trihexyphenidyl
Even low-dose anticholinergic medications impair salivary secretion by 20-30% by blocking muscarinic receptors on salivary gland myoepithelial cells. Concurrent multiple medications have additive effects.

Systemic Diseases Causing Hyposalivation

  • Sjögren's syndrome: Autoimmune destruction of salivary glands (primary Sjögren's: USFR <0.1 mL/min in 90% of cases)
  • Diabetes mellitus: Impaired salivary gland function; hyperglycemia increases salivary viscosity, reducing flow by 25-40%
  • Hypertension: Both disease and medications contribute to reduced salivary flow
  • Rheumatoid arthritis: Systemic inflammation affects gland function; medications (methotrexate) worsen hyposalivation
  • HIV/AIDS: Direct viral impact on salivary glands plus medication side effects
  • Parkinson's disease and other neurological conditions: Motor dysfunction and medications impair salivary secretion

Head and Neck Cancer Radiotherapy

Ionizing radiation (2000+ cGy to salivary glands) causes acute salivary gland inflammation, followed by chronic fibrosis and acinar atrophy. Salivary flow reduces by 60-90% immediately post-radiation; recovery is incomplete, with most patients showing permanently reduced function (40-80% reduction compared to baseline) even 12 months post-treatment.

Clinical Management of Xerostomia

Medication Adjustment

If feasible, discuss medication modification with prescribing physician. Options include:

  • Substitute non-anticholinergic alternative (e.g., loratadine or fexofenadine instead of diphenhydramine)
  • Reduce dosage if possible
  • Change timing: take medications before bedtime to coincide with naturally lower salivation

Medication modification resolves xerostomia in 40-50% of patients; impossible in cases where xerostomia-inducing medication is essential.

Saliva Stimulation

Mechanical stimulation: Sugar-free gum (xylitol-containing preferred) or sugar-free lozenges increase salivary flow by 25-35% acutely. Patients should chew gum 3-4 times daily, 10-15 minutes per session. Xylitol (5-10 grams daily in divided doses) additionally provides antimicrobial benefits. Pharmaceutical stimulation: Pilocarpine (Salagen): Cholinergic agonist stimulating parasympathetic salivary secretion. Dose: 5 mg three times daily; onset of benefit 1-3 weeks. Increases salivary flow by 30-50% in responsive patients. Contraindicated in patients with asthma, narrow-angle glaucoma, cardiac arrhythmias, or uncontrolled hypertension. Side effects include sweating (20%), urinary frequency (10%), blurred vision (8%). Cevimeline (Evoxac): Muscarinic receptor agonist. Dose: 30 mg three times daily. Increases salivary flow by 30-50%. Better tolerated than pilocarpine in many patients; fewer systemic side effects. Same contraindications as pilocarpine.

Pharmaceutical salivary stimulation is effective only when salivary tissue retains function; non-responsive in severe Sjögren's syndrome with advanced gland destruction.

Saliva Substitutes and Lubricants

For patients unresponsive to stimulation, saliva substitutes provide symptomatic relief:

  • Carboxymethyl cellulose (CMC)-based: Biotène, Oral-B Dry Mouth Liquid—provide lubrication and temporary moistening (1-2 hours duration)
  • Hyaluronic acid-based: Improved mucosal protection through increased mucosal thickness
  • Mucin-based: More closely mimic natural saliva composition
Apply after eating, before bedtime, and throughout day as needed. Relief is symptomatic only; does not provide antimicrobial or buffering protection of natural saliva.

Enhanced Preventive Care

Xerostomia patients require aggressive preventive protocols:

Fluoride regimens:
  • High-concentration topical fluoride: 5000 ppm sodium fluoride gel applied 3-5 minutes daily (custom tray or brush-on application)
  • Professional fluoride varnish: 22,600 ppm (Duraphat 50 mg/mL) applied semi-annually or quarterly
Enhanced fluoride provides 40-50% additional caries reduction compared to standard fluoride protocols in xerostomia patients. Antimicrobial therapy:
  • Chlorhexidine 0.12% rinses: 30-60 seconds, twice daily (limit to 2-4 weeks to prevent staining/resistance; can repeat after 4-6 week washout)
  • Cetylpyridinium chloride (CPC) rinses: 0.07%, twice daily, for extended use (no staining concerns)
  • Xylitol mouthwash (5% concentration): twice daily, for combined antimicrobial and pH buffering benefits
Dietary modifications:
  • Avoid acidic beverages (soda, sports drinks, fruit juice); limit to mealtimes
  • Avoid frequent carbohydrate consumption; restrict to 3 mealtimes daily
  • Avoid alcohol and tobacco; both worsen xerostomia symptoms
  • Increase water consumption throughout day (8-10 glasses); carry water bottle for frequent sipping
Recall scheduling: 3-month intervals for high-risk xerostomia patients (severe reduction, Sjögren's syndrome, post-radiation) vs. 6-month intervals for mild-moderate reduction. Oral hygiene: Electric toothbrush 2-3 times daily with high-fluoride toothpaste (5000 ppm); daily interdental cleaning with floss or interdental brush.

Fungal Infection Management

Xerostomia predisposes to oral candidiasis (Candida albicans overgrowth). Clinical presentation includes erythematous patches, white pseudomembranes (pseudomembranous candidiasis), angular cheilitis, or chronic atrophic glossitis.

Treatment protocols:
  • Miconazole oral gel (2%): 5 mL, 4 times daily, applied to affected areas; continue 7-14 days after symptoms resolve
  • Nystatin suspension (100,000 units/mL): 5 mL (swish and swallow), 4 times daily; limited efficacy due to rapid esophageal transit
  • Clotrimazole troches (10 mg): dissolve one 4-5 times daily; superior to suspension in some patients
  • Systemic fluconazole: 100 mg once daily for 7-14 days; reserved for persistent or recurrent candidiasis unresponsive to topical therapy
Prevention through antimicrobial rinses (chlorhexidine, CPC) reduces candidiasis incidence by 50-70% in high-risk patients.

Special Populations

Post-Radiation Cancer Patients

Salivary gland protection during head/neck radiotherapy:

  • Amifostine (Ethyol): Cytoprotectant reducing radiation-induced salivary damage by 40-60% when given IV 15 minutes before radiotherapy. Cost and side effects limit use.
  • Saliva substitutes and fluoride regimens essential indefinitely post-treatment
  • Pilocarpine 5 mg three times daily may partially restore salivary function if initiated within 3-4 months post-radiation
  • Intensity-modulated radiation therapy (IMRT) reduces salivary gland exposure compared to conventional radiation, preserving more function

Sjögren's Syndrome Patients

Primary Sjögren's syndrome typically requires systemic immunosuppressive therapy (hydroxychloroquine, methotrexate) directed at underlying disease, plus aggressive local oral management:

  • Pilocarpine/cevimeline for salivary stimulation
  • Intensive fluoride and antimicrobial therapy
  • Frequent professional monitoring (every 2-3 months) for early candidiasis/caries detection
  • Saliva substitutes for comfort

Summary: Clinical Implications

Saliva is essential for caries prevention, periodontal health, and oral comfort through antimicrobial, buffering, and mechanical protective mechanisms. Xerostomia (reduced salivary flow) dramatically increases caries, candidiasis, and periodontal disease risk. Assessment via salivary flow rate testing and buffering capacity quantification guides treatment planning. Management includes medication adjustment when possible, saliva stimulation (mechanical or pharmaceutical), enhanced preventive care (fluoride, antimicrobials), and regular monitoring. Understanding salivary function and xerostomia pathology enables clinicians to implement individualized prevention and treatment protocols significantly improving outcomes in affected patients.